Hansa Biopharma AB (publ) (STO:HNSA)
Sweden · Delayed Price · Currency is SEK 46.68
+3.90 (9.12%)
Sep 2, 2026, 5:29 PM CET
Hansa Biopharma AB Revenue
Hansa Biopharma AB had revenue of 48.10M SEK in the quarter ending June 30, 2026, a decrease of -2.09%. This brings the company's revenue in the last twelve months to 189.46M, down -3.57% year-over-year. In the year 2025, Hansa Biopharma AB had annual revenue of 222.27M with 29.74% growth.
Revenue (ttm)
189.46M
Revenue Growth
-3.57%
P/S Ratio
22.98
Revenue / Employee
1.45M
Employees
131
Market Cap
4.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 222.27M | 50.95M | 29.74% |
| Dec 31, 2024 | 171.32M | 37.22M | 27.76% |
| Dec 31, 2023 | 134.09M | -20.43M | -13.22% |
| Dec 31, 2022 | 154.53M | 120.65M | 356.12% |
| Dec 31, 2021 | 33.88M | 27.78M | 455.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 424.56M |
| Genovis AB (publ.) | 136.99M |
| AlzeCure Pharma AB | 97.33M |
| Oncopeptides AB | 95.15M |
| Egetis Therapeutics AB | 66.00M |
| BioInvent International AB | 32.51M |
| Medivir AB | 8.71M |
| Vicore Pharma Holding AB | 3.99M |
Hansa Biopharma AB News
- 15 days ago - Will Australia's First Idefirix Transplant Pave Way For Hansa's PDUFA Decision In December 2026? - Nasdaq
- 15 days ago - Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia - PRNewsWire
- 6 weeks ago - Hansa Biopharma AB Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - Hansa Biopharma AB Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Hansa Biopharma AB Slides: Q2 2026 - Filings
- 2 months ago - Hansa Biopharma AB Slides: Corporate presentation - Filings
- 2 months ago - Hansa Biopharma participating in Wedbush PacGrow Renal Summit - PRNewsWire
- 2 months ago - Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA - PRNewsWire